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ABSTRACT The lung clearance index (LCI) from the multiple-breath washout (MBW) test is a
promising surveillance tool for pre-school children with cystic fibrosis (CF). Current guidelines for MBW
testing recommend that three acceptable trials are required. However, success rates to achieve these criteria
are low in children aged <7 years and feasibility may improve with modified pre-school criteria that
accepts tests with two acceptable trials. This study aimed to determine if relationships between LCI and
clinical outcomes of CF lung disease differ when only two acceptable MBW trials are assessed.
Healthy children and children with CF aged 3–6 years were recruited for MBW testing. Children with
CF also underwent bronchoalveolar lavage fluid collection and a chest computed tomography scan.
MBW feasibility increased from 46% to 75% when tests with two trials were deemed acceptable
compared with tests where three acceptable trials were required. Relationships between MBW outcomes
and markers of pulmonary inflammation, infection and structural lung disease were not different between
tests with three acceptable trials compared with tests with two acceptable trials.
This study indicates that pre-school MBW data from two acceptable trials may provide sufficient
information on ventilation distribution if three acceptable trials are not possible.
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Introduction
The lung clearance index (LCI) is a measure of ventilation distribution obtained from the multiple-breath
washout (MBW) test [1]. As the MBW test uses relaxed tidal breathing without the requirement of any
maximal effort, it is an attractive test for infants and pre-school-aged children [2]. LCI is abnormal in a
significant proportion of pre-school children with cystic fibrosis (CF), and correlates with the presence and
extent of structural lung disease detected via chest computed tomography (CT) [3, 4] and lower
respiratory tract inflammation and infection [5–7]. These data suggest that MBW is sensitive to underlying
lung disease in young children with CF.
There is growing interest in the use of MBW in paediatric CF clinical care, research and therapeutic
trials. The 2013 European Respiratory Society (ERS)/American Thoracic Society (ATS) consensus
statement for inert gas washout testing recommends that at least three technically acceptable trials be
performed for the test to be considered acceptable; however, this document also states that data may be
reported if only two acceptable trials are available [1]. MBW testing in pre-school children may require
many attempts to obtain three technically acceptable trials, thereby reducing feasibility in the clinic
setting [8]. Due to the low feasibility associated with obtaining three successful MBW trials in pre-school
children, many studies already report data from tests with only two acceptable trials and have noted
increased feasibility using this approach [9, 10]. These studies suggest that MBW test criteria may need to
be amended for the pre-school age range to allow data to be reported from tests with only two acceptable
MBW trials.
Ideally, it is essential that improved MBW feasibility does not reduce sensitivity and specificity to detect
underlying disease. This study aimed to determine if relationships between LCI and clinical outcomes of
CF lung disease are different when only two acceptable MBW trials are assessed. We hypothesise that
feasibility would improve when two acceptable MBW trials were required compared with three acceptable
trials, and that associations between LCI and clinical markers of CF lung disease would not differ between
tests with three versus two MBW trials. We examined this by performing a paired analysis between MBW
outcomes from the first two trials versus all trials in visits whereby at least three acceptable trials were
obtained. Furthermore, we examined group differences in MBW outcomes between visits with at least two
acceptable trials versus visits with at least three acceptable trials to determine if changing the trial
acceptability criteria impacted associations with clinical markers of disease.
Methods
Study population
Children with CF enrolled in the Australian Respiratory Early Surveillance Team for Cystic Fibrosis
(AREST CF) early surveillance programme in Princess Margaret Hospital (Perth, Australia) and The Royal
Children’s Hospital (Parkville, Australia) between November 2012 and June 2016 were eligible to
participate in this study. This programme starts following diagnosis via newborn screening at 3 months
and involves annual age-appropriate lung function testing a few days prior to the child’s annual review
visit, which includes bronchoalveolar lavage (BAL) fluid collection via bronchoscopy and/or chest CT until
the age of 6 years. As part of a larger multicentre longitudinal study, MBW data from children with CF at
the Riley Hospital for Children (Indianapolis, IN, USA) recruited between May 2015 and June 2016 were
also included in this study. These children underwent MBW testing using the same equipment and
protocol as the AREST CF centres, and attended a study visit for MBW testing scheduled around a
bronchoscopy and chest CT. Children with no history of respiratory disease, pre-term birth or asthma
medication use were recruited to perform MBW testing only from the community in Perth and
Melbourne in Australia and in Indianapolis in the USA. The ethics committee of each institution
approved the study and parents gave informed consent to each aspect of the study.
Multiple-breath washout test
MBW was performing using 100% oxygen to washout resident nitrogen from the lung with the Exhalyzer
D system (EcoMedics, Duernten, Switzerland) and associated Spiroware software (version 3.1.6) [3].
Children performed the test seated using a noseclip and low dead space snorkel-like mouthpiece
(EcoMedics). At each visit children aimed to achieve three acceptable trials according to ERS/ATS
consensus criteria [1] and underwent qualitative quality control assessment [11]. As per the current
recommendation, MBW trials with functional residual capacity (FRC) values that differed by >25% from
the median were excluded [1]. Measures of FRC, LCI, the first moment ratio (M1/M0) and the second
moment ratio (M2/M0) were reported. MBW tests were categorised as 1) all acceptable data (two or more
acceptable trials): MBW tests with two or more acceptable trials; 2) three or more acceptable trials: MBW
tests with three or more acceptable trials; and 3) two acceptable trials: MBW tests with only two
acceptable trials.
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Bronchoalveolar lavage
A bronchoscopy was performed within 3 days after MBW testing for the collection of BAL fluid in
children with CF only for the detection of bacteria, viruses and fungi using standard microbiological
culture techniques, and for the quantification of total and differential inflammatory cell counts and
measurement of free neutrophil elastase activity [12]. A colony count for a specific organism (excluding
mixed oral flora) >104 CFU·mL–1 was defined as a pulmonary infection. Bacterial pathogens known to
elicit a pro-inflammatory response when isolated from the lower respiratory tract (Pseudomonas
aeruginosa, Staphylococcus aureus, Haemophilus influenzae, Streptococcus pneumonia and Aspergillus
species) were described as pro-inflammatory pathogens [13].
Chest computed tomography
Chest CT under general anaesthesia was performed prior to bronchoscopy on children with CF.
Volumetric inspiratory scans were obtained at a positive airway opening pressure of 25 cmH2O and
volumetric or limited slice expiratory scans were obtained at an airway opening pressure of 0 cmH2O as
described previously [3]. CT scans were scored using the quantitative Perth–Rotterdam Annotated Grid
Morphometric Analysis for Cystic Fibrosis (PRAGMA-CF). The separate proportions of total structural
lung disease, bronchiectasis and trapped air were reported [14].
Statistical analysis
Comparisons of MBW outcomes in children with CF and healthy children were performed using t-tests,
while comparisons of proportional differences were performed using Chi-squared tests. Associations
between MBW outcomes with respiratory infection, inflammation and structural lung disease outcomes
were calculated using linear mixed effects models with random intercepts for repeated visits to account for
clustering. Linear mixed effects models were used to compare the relationships between clinical markers of
lung disease with MBW outcomes derived from 1) all trials of children with CF who achieved three or
more acceptable trials, 2) the first two trials of children who achieved three or more acceptable trials and
3) the first two trials of children who achieved two or more acceptable trials. Fixed regression coefficients
of mixed effects models between two and three MBW trials were compared using the z-test [15].
Sensitivity and specificity were also calculated together with 95% exact binomial confidence intervals.
Analyses were performed using SPSS version 23 (IBM, St Leonards, Australia) and Stata version 13.0
(StataCorp, College Station, TX, USA).
Results
Study population
MBW testing was performed in 90 children with CF (149 visits) and 56 healthy children (72 visits) aged
3–6 years (figure 1). There were no differences in age, height or weight z-scores and FRC between CF and
healthy children. Ventilation distribution outcomes (LCI, M1/M0 and M2/M0) were significantly higher in
children with CF compared with healthy controls (p<0.001) (table 1).
The overall success rate to obtain at least three acceptable MBW trials in pre-school children was 46%.
Overall feasibility to obtain at least two acceptable MBW trials was 75%, which was significantly higher
Cystic fibrosis
n=90 (149 visits)
n=71 (104 visits)
Three or more trials
n=49 (63 visits)
Three or more trials
n=40 (43 visits)
Two trials
n=22 (41 visits)
Two trials
n=7 (18 visits)
Healthy
n=56 (72 visits)
n=47 (61 visits)Two or more trials
MBW attempted
FIGURE 1 Flowchart of children with cystic fibrosis and healthy children enrolled in this study. MBW:
multiple-breath washout.
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than the feasibility to obtain three acceptable trials (p<0.001) (figure 1). MBW feasibility was higher in
healthy children compared with children with CF (p<0.001) (table 2).
In the overall population of children with CF who obtained two or more acceptable MBW trials, 48% had
a respiratory infection and 33% had an infection with a pro-inflammatory pathogen. Neutrophil elastase
was detected in 35% of BAL fluid samples, while bronchiectasis was found to be present in 71% of chest
CT scans (table 1). The presence of a respiratory infection was the only clinical outcome in CF to be
significantly different when compared between children who were able to perform three or more MBW
trials and children who achieved only two trials (table 1).
Paired analysis between the first two trials and all trials from visits with three or more
acceptable MBW trials
We aimed to determine if MBW outcomes averaged from the first two MBW trials collected from a testing
session had the same ability to detect CF lung disease as the MBW outcomes averaged from all the trials
in children who obtained three or more MBW trials. We performed a paired statistical analysis comparing
MBW outcomes from the first two trials and all trials from an individual testing session in the subset of
children who obtained three or more MBW trials.
Mean FRC, LCI and moment ratios calculated from the first two trials were not different to the values
calculated from all trials (FRC, p=0.89; LCI, p=0.84; M1/M0, p=0.95; M2/M0, p=0.94) (figure 2 and
TABLE 1 Demographics of children with cystic fibrosis (CF) and healthy children for all visits with two or more acceptable
multiple-breath washout (MBW) trials, visits with three or more acceptable MBW trials and visits with only two acceptable
MBW trials obtained within a single testing session
All visits (two or more
acceptable trials)
Three or more acceptable
trials
Two acceptable trials
CF Healthy CF Healthy CF Healthy
Subjects 71 47 49 36 22 11
Test occasions 104 61 66 42 38 19
Age years 5.1±1.0 4.8±1.1 5.0±1.0 4.8±1.1 5.1±1.0 5.0±0.8
Male 31 (44) 22 (54) 27 (43) 19 (53) 15 (39) 6 (55)
Height cm 109.9±8.8 108.8±8.2 109.7±8.8 108.8±8.2 108.4±8.9 111.1±7.1
Weight kg 19.4±3.7 19.2±3.9 19.7±3.8 19.2±3.9 18.9±3.5 21.0±5.1
Height z-score −0.08±1.0 0.17±1.0 0.04±1.1 0.09±1.1 −0.27±0.95 0.34±0.95
Weight z-score 0.32±0.89 0.51±1.2 0.44±0.93 0.34±1.0 0.12±0.78 0.84±1.5
Multiple-breath washout test
Functional residual capacity L 0.88±0.23 0.85±0.18 0.87±0.25 0.87±0.17 0.89±0.21 0.94±0.17
Lung clearance index 8.13±1.54 7.10±0.60*** 8.19±1.50 6.84±0.63*** 8.05±1.66 6.69±0.48***
First moment ratio 1.78±0.31 1.65±0.12*** 1.81±0.31 1.58±0.14*** 1.75±0.32 1.52±0.10**
Second moment ratio 6.91±2.79 5.54±0.87*** 7.11±2.83 5.07±0.97*** 6.63±2.82 4.62±0.59**
Respiratory infection
Any infection 47/97 (48) 24/60 (40) 23/37 (62)*
Infection with a pro-inflammatory pathogen 32/97 (33) 17/60 (28) 15/38 (39)
Inflammation
Total cell count ×106 mL−1 8.13±14.0 8.93±17.2 6.32±5.16
Macrophages % 75.1±23.4 76.2±23.1 79.8±18.3
Neutrophils % 23.3±23.0 23.0±23.1 19.3±18.8
Neutrophil elastase present 32/92 (35) 18/55 (33) 14/37 (38)
Neutrophil elastase ng·mL−1 874.4±2155.0 904.7±2067.6 1231.1±3127.9
Interleukin-8 pg·mL−1 3227.34±7826.1 4228.2±9674.7 1454.7±2118.0
Structural lung disease
Bronchiectasis present 46/65 (71) 33/49 (67) 13/16 (81)
Bronchiectasis extent % 1.25±2.89 1.11±2.51 1.67±4.09
Air trapping present 52/65 (80) 35/49 (71) 13/16 (81)
Air trapping extent % 5.10±10.1 4.65±8.04 6.14±15.5
Structural lung disease extent % 4.04±3.56 3.96±2.69 3.91±5.68
Data are presented as n, mean±SD, n (%) or n/N (%). z-scores for height and weight were calculated using World Health Organization Child
Growth Standards [16, 17]. Demographics and MBW outcomes were compared between children with CF and healthy children; MBW
outcomes, demographics and clinical data were compared between visits with three or more acceptable trials and visits with only two
acceptable trials. *: p<0.05; **: p<0.01; ***: p<0.001.
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table 3). There were no differences in the ability of LCI, M1/M0 and M2/M0 calculated from the first two
trials to discriminate between children with CF and healthy children compared with values from all trials.
When MBW outcomes were calculated from all MBW trials, 57% of children with CF had abnormal LCI,
60% had abnormal M1/M0 and 68% had abnormal M2/M0 using cut-offs derived from a previous study
from our group [3]. When MBW outcomes were calculated from the first two trials, 57% of children with
CF had abnormal LCI, 59% had abnormal M1/M0 and 65% had abnormal M2/M0 using the same cut-off
values. There were no differences between these proportions when comparing MBW outcomes from all
trials versus the first two trials.
There were no significant differences between the coefficients of associations with pulmonary
inflammation, infection and structural lung disease between LCI, M1/M0 and M2/M0 calculated from the
first two MBW trials and all MBW trials in children who could obtain three or more acceptable trials
(table 3).
Group comparison between visits with two or more acceptable trials and three or more
acceptable trials
To determine if changing the MBW acceptability criteria from requiring at least three acceptable trials to
two acceptable trials affected clinical utility, we compared MBW outcomes and associations with clinical
markers of disease between visits with two or more acceptable trials and visits with three or more
acceptable trials. We found no significant differences between MBW outcomes between the two groups.
TABLE 2 Success rates of obtaining acceptable and repeatable multiple-breath washout
measurements in pre-school-aged children when three or more trials or two or more trials
were deemed acceptable
Age
years
Cystic fibrosis Healthy
Three or more
acceptable trials
Two or more
acceptable trials
Three or more
acceptable trials
Two or more
acceptable trials
3 7/21 (33) 14/21 (67)* 10/14 (71) 13/14 (93)
4 18/38 (47) 27/38 (71)* 9/17 (53) 15/17 (88)*
5 22/49 (45) 35/49 (71)** 14/26 (54) 22/26 (85)*
6 28/41 (68)* 9/15 (60) 11/15 (73)
Overall 66/149 (44) 104/149 (70)*** 42/72 (58) 61/72 (85)***
Data are presented as n/N (%). The Chi-squared test was used to compare differences in proportions
between visits with three or more acceptable trials and two or more acceptable trials. *: p<0.05;
**: p<0.01; ***: p<0.001.
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FIGURE 2 Differences in a) functional residual capacity (FRC) and b) lung clearance index (LCI) when using all
trials in comparison with only the first two trials from children who completed three or more acceptable
trials. A paired t-test was performed to compare the differences in FRC and LCI values.
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Children with CF in both groups had significantly higher LCI, M1/M0 and M2/M0 compared with
healthy children (table 1).
In both groups there were associations between MBW outcomes with markers of pulmonary inflammation,
including neutrophil cells, neutrophil elastase and interleukin-8 concentrations, but not with structural
lung disease (table 4). Strengths of associations were stronger in the group with two or more acceptable
trials compared with the group with three or more acceptable trials with all markers of pulmonary
inflammation. Significant associations were seen in the two or more acceptable trials group for total cell
counts, but not in the three or more acceptable trials group. Further testing of the equality of mixed effects
model coefficients of association between MBW test outcomes with inflammation and structural lung
disease found that the coefficients were not significantly different.
The sensitivity of abnormal MBW outcomes to indicate the presence of a respiratory infection was higher
in the group with two or more acceptable trials compared with the group with three or more acceptable
trials (table 5). The sensitivity and specificity of abnormal MBW outcomes to indicate the presence of
bronchiectasis was higher in the group with two or more acceptable trials compared with the group with
three or more acceptable trials.
Discussion
This study shows that there were no significant differences between MBW outcomes or associations with
clinical markers of disease when MBW outcomes are calculated from two acceptable trials versus three or
more acceptable trials. MBW outcomes from two trials provide the same ability to discriminate between
healthy children and children with CF as when using MBW outcomes from three trials. In the paired
analysis of children with CF, markers of ventilation distribution (LCI, M1/M0 and M2/M0) calculated
from the first two trials and all trials had the same ability to detect the presence and extent of pulmonary
inflammation, infection and structural lung disease. In addition, changing the acceptability criteria from at
least three acceptable trials to two acceptable trials in the entire population significantly improved MBW
test feasibility but did not change MBW outcomes or associations with clinical markers of disease in the
same cohort. Moreover, the findings from this study suggest that by excluding subjects who are unable to
complete three acceptable trials, the ability to detect associations with clinical markers of disease may be
diminished due to reduced power. This study demonstrates that results from two acceptable trials provide
sufficient information on ventilation distribution if three trials are unable to be obtained.
In this study, we only included children within the pre-school age range, a population known to be
particularly challenging for measuring lung function [2]. We show that the success rate of obtaining three
or more acceptable and repeatable trials in pre-school age children is 44% in children with CF and 58% in
healthy children; however, by accepting MBW tests with two acceptable trials this is markedly improved to
70% in CF and 85% in controls, therefore significantly improving feasibility of the MBW test in pre-school
TABLE 3 Relationship between multiple-breath washout (MBW) test outcomes with inflammation and structural lung disease
in children with cystic fibrosis when MBW outcomes were calculated from all trials obtained compared with the first two trials
obtained in visits with three or more acceptable trials
Lung clearance index First moment ratio Second moment ratio
All trials First two trials All trials First two trials All trials First two trials
MBW outcomes 8.19±1.50 8.19±1.46 1.81±0.31 1.80±0.30 7.11±2.83 7.04±2.84
Pulmonary inflammation
Total cell count 0.35 (−0.04–0.75) 0.40 (−0.01–0.80) 0.06 (−0.02–0.14) 0.08 (−0.01–0.17) 0.50 (−0.21–1.22) 0.65 (−0.11–1.41)
Neutrophil cells 0.38 (0.12–0.63)* 0.40 (0.14–0.66)* 0.07 (0.01–0.12)* 0.07 (0.01–0.13)* 0.55 (0.07–1.03)* 0.58 (0.06–1.10)*
Neutrophil elastase
concentration
0.28 (0.04–0.53)* 0.29 (0.04–0.54)* 0.06 (0.01–0.11)* 0.07 (0.01–0.12)* 0.49 (0.05–0.93)* 0.56 (0.08–1.03)*
Interleukin-8 concentration 0.31 (0.08–0.53)* 0.32 (0.09–0.55)* 0.05 (0.01–0.10)* 0.06 (0.01–0.11)* 0.45 (0.04–0.87)* 0.48 (0.04–0.93)*
Structural lung disease
%Dis 0.08 (−0.06–0.23) 0.07 (−0.08–0.22) 0.02 (−0.01–0.05) 0.02 (−0.02–0.05) 0.13 (−0.14–0.39) 0.12 (−0.17–0.41)
%Bx 0.07 (−0.09–0.23) 0.06 (−0.10–0.22) 0.01 (−0.02–0.04) 0.01 (−0.02–0.05) 0.10 (−0.19–0.39) 0.08 (−0.23–0.40)
%TA 0.03 (−0.02–0.08) 0.04 (−0.01–0.09) 0.01 (−0.01–0.01) 0.01 (−0.01–0.02) 0.05 (−0.04–0.14) 0.06 (−0.03–0.16)
The raw MBW outcomes are presented, and the coefficients for the linear mixed effects model (adjusted for test centre) for associations with
markers of pulmonary inflammation and structural lung disease are presented with 95% confidence intervals. %Dis: volume proportion of
the lung with airway disease; %Bx: volume proportion of the lung with bronchiectasis; %TA: volume proportion of the lung with trapped air.
*: p<0.05.
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children. In our study, the higher feasibility in healthy children may be attributed to study visits in CF
patients being scheduled around other clinical appointments, with limited time (<30 min) to complete the
MBW testing compared with healthy control participants who attended a study visit to solely complete
lung function testing. Previous feasibility studies on MBW testing in pre-school children using commercial
equipment have also demonstrated higher feasibility when two trials were accepted compared with three
trials. Feasibility to obtain three trials was 24% when the testing time was restricted to 20 min, but this
increased to 60% when two trials were accepted [8]. Another study assessing feasibility of MBW testing in
a clinical sitting showed an increase in feasibility with age, with an overall success rate of 80% in children
aged 3–6 years; however, the study only reported acceptability for tests with two or more repeatable trials
[9]. Overall, MBW feasibility in our study is comparable to that of previously published studies.
There have been many studies that have aimed to improve MBW test feasibility. Studies suggest that
feasibility is higher when using facemasks rather than mouthpieces [18]. An early study of MBW testing in
pre-school children showed that the use of a mask to obtain three MBW trials in pre-school children
TABLE 4 Group comparisons for the relationship between multiple-breath washout test outcomes with inflammation and
structural lung disease in children with cystic fibrosis when results from the first two trials of children who could perform
three or more acceptable trials# were compared with children who could perform two or more acceptable trials¶
Lung clearance index First moment ratio Second moment ratio
Three or more
acceptable trials
Two or more
acceptable trials
Three or more
acceptable trials
Two or more
acceptable trials
Three or more
acceptable trials
Two or more
acceptable trials
Pulmonary
inflammation
Total cell counts 0.40 (−0.01–0.80) 0.66 (0.34–0.98)*** 0.08 (−0.01–0.17) 0.13 (0.06–0.20)*** 0.65 (−0.11–1.41) 1.08 (0.49–1.68)***
Neutrophil cells 0.40 (0.14–0.66)* 0.44 (0.21–0.67)*** 0.07 (0.01–0.13)* 0.08 (0.03–0.13)** 0.58 (0.06–1.10)* 0.72 (0.30–1.14)**
Neutrophil
elastase
concentration
0.29 (0.04–0.54)* 0.29 (0.10–0.48)*** 0.07 (0.01–0.12)* 0.06 (0.02–0.10)** 0.56 (0.08–1.03)* 0.53 (0.19–0.86)**
Interleukin-8
concentration
0.32 (0.09–0.55)* 0.25 (0.08–0.42)** 0.06 (0.01–0.11)* 0.05 (0.01–0.08)** 0.48 (0.04–0.93)* 0.40 (0.10–0.71)**
Structural lung
disease
%Dis 0.07 (−0.08–0.22) 0.09 (−0.01–0.19) 0.02 (−0.02–0.05) 0.02 (−0.01–0.04) 0.12 (−0.17–0.41) 0.14 (−0.05–0.33)
%Bx 0.06 (−0.10–0.22) 0.07 (−0.06–0.20) 0.01 (−0.02–0.05) 0.01 (−0.01–0.04) 0.08 (−0.23–0.40) 0.10 (−0.13–0.34)
%TA 0.04 (−0.01–0.09) 0.03 (−0.01–0.07) 0.01 (−0.01–0.02) 0.01 (−0.01–0.01) 0.06 (−0.03–0.16) 0.05 (−0.01–0.12)
The coefficient for the linear mixed effects model (adjusted for test centre) is presented with 95% confidence intervals. %Dis: volume
proportion of the lung with airway disease; %Bx: volume proportion of the lung with bronchiectasis; %TA: volume proportion of the lung with
trapped air. #: n=49; ¶: n=71. *: p<0.05; **: p<0.01; ***: p<0.001.
TABLE 5 Ability of the multiple-breath washout test to detect the presence of neutrophil elastase, respiratory infections and
structural lung disease in pre-school children with cystic fibrosis who achieved three or more and two or more acceptable
trials
Lung clearance index First moment ratio Second moment ratio
Three or more
acceptable trials
Two or more
acceptable trials
Three or more
acceptable trials
Two or more
acceptable trials
Three or more
acceptable trials
Two or more
acceptable trials
Neutrophil elastase
Sensitivity % 83 (59–96) 83 (59–96) 89 (65–99) 89 (65–99) 89 (65–99) 89 (65–99)
Specificity % 61 (43–76) 64 (46–79) 61 (43–76) 64 (46–79) 47 (31–64) 47 (30–65)
Respiratory infection
Sensitivity % 67 (43–85) 70 (47–87) 67 (43–85) 74 (54–87) 71 (48–89) 83 (63–93)
Specificity % 58 (39–75) 56 (38–72) 58 (39–75) 53 (37–68) 42 (25–61) 42 (27–58)
Bronchiectasis
Sensitivity % 66 (46–82) 70 (51–85) 65 (46–82) 69 (50–84) 83 (64–94) 84 (67–95)
Specificity % 59 (33–82) 69 (41–89) 59 (33–82) 63 (35–85) 53 (28–77) 63 (35–85)
Data are presented as median (range).
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achieved an overall success rate of 79% [5]. Feasibility was also higher in healthy children compared with
children with CF in this study. A recent publication demonstrated that feasibility could be improved with
familiarisation, where at the initial visit, pre-school feasibility was 66% to achieve two or more trials and this
increased to 89% at subsequent visits [10]. MBW testing was performed using facemasks and the second
visit performed 1 month after the initial visit. ROBINSON et al. [19] aimed to assess if the MBW test could be
shortened by using two trials rather than three trials, and found that although there was a statistically
significant difference in mean LCI from three tests and the first two tests in school-aged children, the
difference of 0.07 units was not clinically significant. LCI calculated from two technically acceptable tests
provided similar abnormal values as from three tests in CF patients. Another study attempted to shorten
test duration in school-aged children using three MBW trials with a washout to 1/20th of the starting
concentration or two trials to the standard 1/40th concentration. Similar to findings from ROBINSON et al.
[19], mean LCI from two trials was similar to LCI from three trials and also had a high sensitivity to detect
CF lung disease [20]. A subsequent study, however, showed that while washout to 1/20th of the starting
concentration reduced test duration, it did not improve feasibility in children <3 years of age [9]. Reducing
washout time may not be suitable in patients with mild disease as there is the potential to miss information
on ventilation distribution during later stages of the washout; thus, accepting MBW tests with two
technically acceptable trials may be the most feasible means to increase feasibility in young children.
The strengths of this study are that infection and inflammation information from BAL, as well as
structural lung disease on chest CT, were determined during the same week as MBW testing in children
with CF. Markers of ventilation inhomogeneity therefore reflected the current clinical status of lung health.
A limitation of this study was that we did not include data on test duration. Feasibility in children with CF
for obtaining three trials was also low, possibly due to time constraints during testing or the use of a
mouthpiece rather than a facemask that could potentially reduce feasibility due to leaks, as it is harder to
keep a seal on the mouthpiece, reducing study numbers for the comparisons between two and three or
more trials. As such, we identified stronger associations between MBW and pulmonary inflammation
outcomes in children with CF from the entire cohort, suggesting a stronger effect with increased power.
We recommend that users should collect at least three acceptable MBW trials whenever possible according
to the ERS/ATS consensus statement [1]. However, this study provides evidence that MBW data in
pre-school children reported from only two acceptable trials provide comparable outcomes, ability to
discriminate between health and disease, and associations with clinical markers of CF lung disease as
MBW data reported from three acceptable trials. In addition, by excluding MBW tests with less than two
trials, valid data points may not be included in study analyses. The acceptability of MBW visits with only
two acceptable trials allows for improved feasibility in young children, which may increase participants
eligible for longitudinal assessment of MBW outcomes, and clinical trials utilising MBW data as an
end-point, thus assisting the transition of MBW into the clinical setting.
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